Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Bloom Burton & Co to hold a virtual conference » 09:44
04/21/21
04/21
09:44
04/21/21
09:44
ATBPF

Antibe Therapeutics

$3.40 /

-0.2 (-5.56%)

, CHHHF

CareRx

$5.36 /

+0.505 (+10.41%)

, FUSN

Fusion Pharmaceuticals

$8.39 /

+ (+0.00%)

, HLTRF

HLS Therapeutics

$15.07 /

-1.911 (-11.25%)

, HTLZF

Hamilton Thorne

$1.37 /

+ (+0.00%)

, ONCY

Oncolytics

$3.00 /

+ (+0.00%)

, PROF

Profound Medical

$18.75 /

-0.05 (-0.27%)

, RPTX

Repare Therapeutics

$31.95 /

-0.03 (-0.09%)

, THTX

Theratechnologies

$3.60 /

+ (+0.00%)

, TMDI

Titan Medical

$1.49 /

+ (+0.00%)

, ZYME

Zymeworks

$26.51 /

-0.01 (-0.04%)

Healthcare Investor…

Healthcare Investor Virtual Conference will be held on April 20-21. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$26.51 /

-0.01 (-0.04%)

TMDI Titan Medical
$1.49 /

+ (+0.00%)

THTX Theratechnologies
$3.60 /

+ (+0.00%)

RPTX Repare Therapeutics
$31.95 /

-0.03 (-0.09%)

PROF Profound Medical
$18.75 /

-0.05 (-0.27%)

ONCY Oncolytics
$3.00 /

+ (+0.00%)

HTLZF Hamilton Thorne
$1.37 /

+ (+0.00%)

FUSN Fusion Pharmaceuticals
$8.39 /

+ (+0.00%)

ATBPF Antibe Therapeutics
$3.40 /

-0.2 (-5.56%)

02/25/21 Canaccord
Antibe Therapeutics price target lowered to C$14.50 from C$16.50 at Canaccord
02/10/21 Canaccord
Antibe Therapeutics price target raised to C$16.50 from C$15 at Canaccord
09/24/20 Maxim
Antibe Therapeutics initiated with a Buy at Maxim
07/15/20 Brookline
Antibe Therapeutics initiated with a Buy at Brookline
CHHHF CareRx
$5.36 /

+0.505 (+10.41%)

03/11/21 Canaccord
CareRx price target raised to C$7 from C$6.50 at Canaccord
02/04/21 Desjardins
CareRx initiated with a Buy at Desjardins
12/15/20 Industrial Alliance
CareRx initiated with a Buy at Industrial Alliance
06/29/20 Stifel
CareRx initiated with a Buy at Stifel
FUSN Fusion Pharmaceuticals
$8.39 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
HLTRF HLS Therapeutics
$15.07 /

-1.911 (-11.25%)

03/24/21 Raymond James
HLS Therapeutics price target raised to C$28 from C$27 at Raymond James
01/21/21 Raymond James
HLS Therapeutics initiated with an Outperform at Raymond James
11/06/20 Canaccord
HLS Therapeutics price target raised to C$30.50 from C$29 at Canaccord
10/01/20 Clarus
HLS Therapeutics price target raised to C$33.25 from C$31 at Clarus
HTLZF Hamilton Thorne
$1.37 /

+ (+0.00%)

04/16/21 Stifel
Stifel starts Hamilton Thorne at Buy, says growth will 'soon double'
04/15/21 Stifel
Hamilton Thorne initiated with a Buy at Stifel
06/01/20 Canaccord
Hamilton Thorne price target raised to C$1.75 from C$1.50 at Canaccord
04/27/20 Industrial Alliance
Hamilton Thorne initiated with a Buy at Industrial Alliance
ONCY Oncolytics
$3.00 /

+ (+0.00%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
PROF Profound Medical
$18.75 /

-0.05 (-0.27%)

03/03/21 Alliance Global Partners
Alliance Global still bullish on Profound Medical after 'mixed' Q4
01/25/21 Lake Street
Profound Medical price target raised to $32 from $27 at Lake Street
01/07/21 Alliance Global Partners
Profound Medical price target raised to $28.25 from $20.25 at Alliance Global
09/15/20 Jefferies
Profound Medical initiated with a Buy at Jefferies
RPTX Repare Therapeutics
$31.95 /

-0.03 (-0.09%)

03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
12/29/20 Northland
Northland ups Repare Therapeutics price target to $42, calls a Top Pick for 2021
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Northland
Repare Therapeutics initiated with an Outperform at Northland
THTX Theratechnologies
$3.60 /

+ (+0.00%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
TMDI Titan Medical
$1.49 /

+ (+0.00%)

04/06/21 Oppenheimer
Opco starts 'attractive micro-cap play' Titan Medical with Outperform
04/06/21 Oppenheimer
Titan Medical initiated with an Outperform at Oppenheimer
ZYME Zymeworks
$26.51 /

-0.01 (-0.04%)

03/30/21 Credit Suisse
Zymeworks initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Zymeworks initiated with an Outperform at Credit Suisse
02/25/21 SVB Leerink
Zymeworks downgraded to Market Perform at SVB Leerink
02/25/21 SVB Leerink
Zymeworks downgraded to Market Perform from Outperform at SVB Leerink
ZYME Zymeworks
$26.51 /

-0.01 (-0.04%)

TMDI Titan Medical
$1.49 /

+ (+0.00%)

THTX Theratechnologies
$3.60 /

+ (+0.00%)

RPTX Repare Therapeutics
$31.95 /

-0.03 (-0.09%)

ONCY Oncolytics
$3.00 /

+ (+0.00%)

HTLZF Hamilton Thorne
$1.37 /

+ (+0.00%)

FUSN Fusion Pharmaceuticals
$8.39 /

+ (+0.00%)

  • 06
    Jan
  • 16
    Jul
  • 26
    Jun
  • 19
    Jun
RPTX Repare Therapeutics
$31.95 /

-0.03 (-0.09%)

FUSN Fusion Pharmaceuticals
$8.39 /

+ (+0.00%)

Conference/Events
Canaccord to hold a virtual conference » 09:39
04/15/21
04/15
09:39
04/15/21
09:39
ONCY

Oncolytics

$3.06 /

-0.08 (-2.55%)

, SESN

Sesen Bio

$2.35 /

+0.015 (+0.64%)

, OLMA

Olema Oncology

$35.84 /

+3.56 (+11.03%)

, SQZ

SQZ Biotechnologies

$13.06 /

-0.12 (-0.91%)

, APTO

Aptose Biosciences

$5.20 /

+0.09 (+1.76%)

, BCEL

Atreca

$12.42 /

+0.83 (+7.16%)

, BNTX

BioNTech

$132.52 /

+3.11 (+2.40%)

Horizons in Oncology…

Horizons in Oncology Virtual Conference to be held on April 15.

ShowHide Related Items >><<
SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

02/17/21 Canaccord
Sesen Bio price target raised to $7 from $5 at Canaccord
02/16/21 Canaccord
Sesen Bio price target raised to $7 from $5 at Canaccord
02/16/21 Jefferies
Jefferies doubles target on Sesen Bio to $6 on 'optimal scenario'
01/25/21 Canaccord
Sesen Bio a must-own small cap for 2021, says Canaccord
OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

03/30/21 Brookline
SQZ Biotechnologies initiated with a Buy at Brookline
01/07/21 Evercore ISI
SQZ Biotechnologies initiated with an Outperform at Evercore ISI
11/24/20 Stifel
SQZ Biotechnologies initiated with a Buy at Stifel
11/24/20 BofA
SQZ Biotechnologies initiated with a Buy at BofA
APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
BCEL Atreca
$12.42 /

+0.83 (+7.16%)

02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BCEL Atreca
$12.42 /

+0.83 (+7.16%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

  • 12
    Feb
  • 19
    Nov
  • 30
    Oct
  • 23
    Jul
  • 16
    Jul
  • 16
    Jul
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

Conference/Events
Oncolytics to hold a Key Opinion Leader conference call » 13:45
04/12/21
04/12
13:45
04/12/21
13:45
ONCY

Oncolytics

$3.60 /

-0.38 (-9.55%)

Management holds a Key…

Management holds a Key Opinion Leader conference call with Drs. Prat (Clinic Barcelona)and Vile (Mayo Clinic) who will discuss AWARE-1 data, the immunotherapeutic effects of Pelareorep in breast cancer and its synergistic activity with CART cell sin solid tumors on April 12 at 2 pm. Webcast Link

ShowHide Related Items >><<
ONCY Oncolytics
$3.60 /

-0.38 (-9.55%)

ONCY Oncolytics
$3.60 /

-0.38 (-9.55%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.60 /

-0.38 (-9.55%)

Conference/Events
Oncolytics to hold a Key Opinion Leader conference call » 08:28
04/12/21
04/12
08:28
04/12/21
08:28
ONCY

Oncolytics

$3.99 /

-0.61 (-13.26%)

Management holds a Key…

Management holds a Key Opinion Leader conference call with Drs. Prat (Clinic Barcelona)and Vile (Mayo Clinic) who will discuss AWARE-1 data, the immunotherapeutic effects of Pelareorep in breast cancer and its synergistic activity with CART cell sin solid tumors on April 12 at 2 pm. Webcast Link

ShowHide Related Items >><<
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

Hot Stocks
Oncolytics presents preclinical data on pelareorep at AACR » 07:15
04/12/21
04/12
07:15
04/12/21
07:15
ONCY

Oncolytics

$3.99 /

-0.61 (-13.26%)

Oncolytics Biotech…

Oncolytics Biotech recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The data are featured in two electronic poster presentations at the American Association for Cancer Research Annual Meeting 2021. Experiments presented in the posters evaluate the mechanisms of therapeutic synergy between pelareorep and anti-cancer agents identified via a non-biased high throughput screening assay. The top results identified in the screen were the poly-ribose polymerase 1 inhibitor talazoparib and the Cyclin-dependent kinase 4/6 inhibitor palbociclib, which are both FDA approved for the treatment of breast cancer. "Preclinical data presented at AACR compel the use of pelareorep to broaden the therapeutic applicability of approved anti-cancer agents," said Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. "Notably, the synergistic interactions between pelareorep and both talazoparib and palbociclib were mediated through immunological effects rather than through the molecular pathways typically associated with PARP-1 and CDK 4/6 inhibition. These findings suggest that pelareorep may expand the mechanisms by which PARP-1 and CDK 4/6 inhibitors exert anti-tumor effects, which may enhance their therapeutic potential."

ShowHide Related Items >><<
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

Hot Stocks
Oncolytics, SOLTI achieve primary endpoint in AWARE-1 study » 07:13
04/12/21
04/12
07:13
04/12/21
07:13
ONCY

Oncolytics

$3.99 /

-0.61 (-13.26%)

Oncolytics Biotech,…

Oncolytics Biotech, together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021.

ShowHide Related Items >><<
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.99 /

-0.61 (-13.26%)

Over a month ago
Syndicate
Oncolytics establishes new $80M at-the-market facility » 07:35
03/05/21
03/05
07:35
03/05/21
07:35
ONCY

Oncolytics

$3.08 /

-0.18 (-5.52%)

Oncolytics Biotech…

Oncolytics Biotech announced that it has entered into an at-the-market equity offering sales agreement with Canaccord Genuity. The ATM allows the company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to $80M. The company has no obligation to sell any shares pursuant to the ATM. Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.

ShowHide Related Items >><<
ONCY Oncolytics
$3.08 /

-0.18 (-5.52%)

ONCY Oncolytics
$3.08 /

-0.18 (-5.52%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.08 /

-0.18 (-5.52%)

Hot Stocks
Oncolytics announces publication of data from pelareorep and CAR T cells study » 07:14
02/23/21
02/23
07:14
02/23/21
07:14
ONCY

Oncolytics

$3.30 /

-0.08 (-2.37%)

Oncolytics Biotech…

Oncolytics Biotech announced publication of an electronic poster at the CAR-TCR Summit Europe 2021 with data from a preclinical study evaluating pelareorep and chimeric antigen receptor, or CAR, T cell combination therapy in solid tumors. Newly published results show that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model, in stark contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. Efficacy of pelareorep-loaded CAR T cell therapy was further enhanced by boosting mice 8 days later with a single intravenous dose of pelareorep, generating highly persistent CAR T cells, inhibition of recurrent tumor growth, and ultimately tumor cures. These synergistic immune effects were specific to pelareorep, as intravenous boosting with VSV did not augment CAR/Pela therapy or prevent the growth of recurrent tumors. Survival data from the preclinical study are shown

ShowHide Related Items >><<
ONCY Oncolytics
$3.30 /

-0.08 (-2.37%)

ONCY Oncolytics
$3.30 /

-0.08 (-2.37%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.30 /

-0.08 (-2.37%)

Initiation
Oncolytics initiated with a Buy at H.C. Wainwright » 06:08
02/17/21
02/17
06:08
02/17/21
06:08
ONCY

Oncolytics

$3.02 /

+0.34 (+12.69%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Oncolytics Biotech with a Buy rating and $15 price target. The company is "on the cusp of demonstrating potential to upend the treatment paradigms of several cancers," Trucchio tells investors in a research note. He believes Oncolytics is well positioned for the "oncolytic virus trend."

ShowHide Related Items >><<
ONCY Oncolytics
$3.02 /

+0.34 (+12.69%)

ONCY Oncolytics
$3.02 /

+0.34 (+12.69%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
ONCY Oncolytics
$3.02 /

+0.34 (+12.69%)

Over a quarter ago
Conference/Events
SABC / CTRC / AACR to co-host San Antonio Breast Cancer Virtual Symposium » 05:55
12/11/20
12/11
05:55
12/11/20
05:55
A

Agilent

$118.84 /

+2.285 (+1.96%)

, AMGN

Amgen

$228.17 /

-1.61 (-0.70%)

, ATNX

Athenex

$11.79 /

-0.31 (-2.56%)

, AZN

AstraZeneca

$53.90 /

-0.14 (-0.26%)

, BMY

Bristol-Myers

$60.21 /

-0.74 (-1.21%)

, BYSI

BeyondSpring

$10.80 /

+0.18 (+1.69%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXAS

Exact Sciences

$132.80 /

+2.29 (+1.75%)

, FMS

Fresenius Medical

$41.52 /

+0.16 (+0.39%)

, NVS

Novartis

$91.66 /

-0.145 (-0.16%)

, NTRA

Natera

$98.70 /

+4.09 (+4.32%)

, NEO

NeoGenomics

$50.19 /

+0.68 (+1.37%)

, MYGN

Myriad Genetics

$19.70 /

+1.03 (+5.52%)

, VCYT

Veracyte

$57.15 /

+2.31 (+4.21%)

, SGEN

Seagen

$186.55 /

+5.14 (+2.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PBYI

Puma Biotechnology

$10.72 /

+0.15 (+1.42%)

, PFE

Pfizer

$41.74 /

-0.11 (-0.26%)

, ONCY

Oncolytics

$2.70 /

-0.63 (-18.92%)

, GH

Guardant Health

$126.07 /

-0.55 (-0.43%)

, LLY

Eli Lilly

$160.97 /

+2.93 (+1.85%)

, MGNX

MacroGenics

$22.70 /

+0.19 (+0.84%)

, MRK

Merck

$82.99 /

-0.54 (-0.65%)

San Antonio Breast Cancer…

San Antonio Breast Cancer Symposium (SABCS), Cancer Therapy & Research Center (CTRC) and the American Association for Cancer Research (AACR) co-host the San Antonio Breast Cancer Virtual Symposium on December 8-11. Webcast Link

ShowHide Related Items >><<
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

ONCY Oncolytics
$2.70 /

-0.63 (-18.92%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

A Agilent
$118.84 /

+2.285 (+1.96%)

12/10/20 SVB Leerink
Agilent price target raised to $130 from $120 at SVB Leerink
12/02/20 Goldman Sachs
Agilent initiated with a Buy at Goldman Sachs
11/25/20
Fly Intel: Top five analyst upgrades
11/25/20 UBS
Agilent upgraded to Buy from Neutral at UBS
AMGN Amgen
$228.17 /

-1.61 (-0.70%)

12/09/20 SVB Leerink
Amgen price target raised to $253 from $243 at SVB Leerink
12/08/20 Piper Sandler
Amgen price target raised to $280 from $270 at Piper Sandler
12/08/20 Ladenburg
Ladenburg upgrades BeiGene to Buy after product approvals, ASH data
11/23/20 Mizuho
Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho
ATNX Athenex
$11.79 /

-0.31 (-2.56%)

10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
09/01/20 RBC Capital
Athenex price target raised to $33 from $31 at RBC Capital
12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

12/07/20
Fly Intel: Top five analyst upgrades
12/07/20 Morgan Stanley
AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
12/01/20 Morgan Stanley
COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley
11/30/20 UBS
AstraZeneca upgraded to Neutral from Sell at UBS
BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

12/09/20 Mizuho
Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
11/30/20 Citi
Bristol-Myers price target raised to $77 from $73 at Citi
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

11/24/20 H.C. Wainwright
BeyondSpring price target lowered to $43 from $46 at H.C. Wainwright
06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

06/08/20 Jefferies
Jefferies downgrades Daiichi Sankyo to Hold with Enhertu seen as priced in
06/08/20 Jefferies
Daiichi Sankyo downgraded to Hold from Buy at Jefferies
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

10/29/20
Fly Intel: Top five analyst downgrades
10/29/20 UBS
Exact Sciences downgraded to Neutral from Buy at UBS
10/28/20
Fly Intel: Top five analyst downgrades
10/28/20 Benchmark
Exact Sciences price target raised to $145 from $110 at Benchmark
FMS Fresenius Medical
$41.52 /

+0.16 (+0.39%)

12/09/20 Morgan Stanley
Fresenius Medical price target raised to EUR 75 from EUR 74 at Morgan Stanley
11/10/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 87 from EUR 97 at Deutsche Bank
11/05/20 UBS
Fresenius Medical price target lowered to EUR 94 from EUR 95 at UBS
11/04/20 Nord/LB
Fresenius Medical upgraded to Buy from Hold at Nord/LB
NVS Novartis
$91.66 /

-0.145 (-0.16%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
NTRA Natera
$98.70 /

+4.09 (+4.32%)

12/02/20 BTIG
Natera price target raised to $105 from $95 at BTIG
11/06/20 JPMorgan
Natera price target raised to $90 from $75 at JPMorgan
11/06/20 Morgan Stanley
Natera price target raised to $87 from $80 at Morgan Stanley
11/06/20 Piper Sandler
Natera price target raised to $92 from $76 at Piper Sandler
NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

12/11/20 BTIG
NeoGenomics initiated with a Buy at BTIG
11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
10/28/20 Needham
NeoGenomics price target raised to $46 from $39 at Needham
10/28/20 Craig-Hallum
NeoGenomics price target raised to $50 from $42 at Craig-Hallum
MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

11/09/20 KeyBanc
Veracyte initiated with a Sector Weight at KeyBanc
11/04/20 BTIG
Veracyte price target raised to $42 from $38 at BTIG
09/09/20 Morgan Stanley
Veracyte initiated with an Underweight at Morgan Stanley
07/31/20 Lake Street
Veracyte price target raised to $40 from $35 at Lake Street
SGEN Seagen
$186.55 /

+5.14 (+2.83%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/22/20 JMP Securities
Seattle Genetics price target raised to $200 from $185 at JMP Securities
09/21/20 Piper Sandler
Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
11/27/20 UBS
Roche price target lowered to CHF 365 from CHF 370 at UBS
11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PFE Pfizer
$41.74 /

-0.11 (-0.26%)

12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
12/07/20 Credit Suisse
Inter Pipeline downgraded to Underperform at Credit Suisse
12/04/20 Barclays
Pfizer price target raised to $37 from $35 at Barclays
ONCY Oncolytics
$2.70 /

-0.63 (-18.92%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
GH Guardant Health
$126.07 /

-0.55 (-0.43%)

11/06/20 JPMorgan
Guardant Health price target raised to $135 from $120 at JPMorgan
09/09/20 Morgan Stanley
Guardant Health initiated with an Overweight at Morgan Stanley
08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
12/02/20 Stifel
Blueprint Medicines initiated with a Hold at Stifel
MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

08/03/20 Citi
MacroGenics downgraded to Neutral from Buy at Citi
06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
MRK Merck
$82.99 /

-0.54 (-0.65%)

12/10/20 Piper Sandler
Piper says NGM Biopharmaceuticals R&D day highlights 'undervaluation' of shares
11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 10
    Sep
  • 05
    Aug
  • 19
    Jun
  • 02
    Jun
  • 30
    Apr
RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.